Drug-Induced Liver Injury and Hepatic Encephalopathy
|
|
- Melina Wilson
- 5 years ago
- Views:
Transcription
1 Drug-Induced Liver Injury and Hepatic Encephalopathy William M. Lee, MD Division of Digestive and Liver Diseases UT Southwestern Medical Center at Dallas Division of Gastroenterology, Hepatology and Nutrition The Ohio State University DILI Pharma/FDA/Academy Meeting No. 12 March 20-21, 2013
2 Disclosures: William M. Lee, MD Research Grants to UTSW Anadys, Boehringer-Ingelheim, BMS, Cumberland, Gilead, Merck, Roche, Vertex, Consulting Lilly, Novartis
3 AIMS Review current thinking about hepatic encephalopathy (HE) and liver failure Compare acetaminophen toxicity with DILI as causes of acute liver failure Discuss current therapies for HE Review current treatment trials in HE
4 DILI Causes Acute Liver Failure Defining Feature is Encephalopathy Most severe form of liver injury but rare, 2000/yr Devastating: survival <10% in earlier era Definition: INR 1.5, any grade enceph, acute illness UNOS Status 1a Fascinating Frustrating Hard to treat Difficult to study
5 Etiology of Acute Liver Failure in the USA Adult Registry (n = 2,000) 46% ALF Study Group, Jan % 12%
6 Comparison of Different ALF Etiology Groups N = 2000 APAP Drug Indeterminate HepA/HepB All Others N=916 n=220 n=245 n=36/142 N=441 Age (median) /43 45 Sex (% F) /44 71 Jaundice (Days) /8 7 Coma 3 (%) /52 38 ALT / Bili (median) / Tx (%) /39 32 Spontaneous Surv (%) Overall Survival (%) / /55 58
7 Two forms of encephalopathy: hyperacute and subacute Hyperacute Acetaminophen Cerebral edema Rapid onset/recovery Early presentation High ALT/low Bili No ascites/some KI Subacute/Chronic idili/aih/hep B/Indeter No cerebral edema Slow onset/poor recovery Late presentation Low ALT/High Bili Frequent ascites/hrs Edema likely indicates that rapid onset yields osmotic changes that cannot be compensated
8 Current Treatment for HE/Cerebral Edema Hyperacute Quiet room No sedation Maintain MAP Mannitol Hypertonic saline Hypothermia Anti-convulsants Subacute/Chronic Low protein diet Lactulose (?) Antibiotics: rifaximin Liver support devices (??) No therapy directed at the cause. Is it really NH 3?
9 32 Year-old male with ALF of indeterminate etiology Admission head CT 48 h after admission
10 Effects of Mannitol or Induced Hypernatremia on Intracranial Hypertension in Patients with ALF ICP (mmhg) 60 N= Before After Hanid, et al. Gut 1980;21:866. Murphy, et al. Hepatology. 2004; 39: 464.
11 Effects of Hypothermia in Patients with ALF and Uncontrolled Intracranial Hypertension Precooling 4 h h ICP (mmhg) CBF (ml/100 g/min) MAP (mmhg) Jalan, et al. Gastroenterology. 2004; 127:1338. N=14; 13 bridged to liver transplantation
12 The STOP-ALF Trial Why Target Ammonia? Associated with hepatic encephalopathy Highly associated with brain edema: Levels of NH3 above mmol/l associated with increased intra-cranial pressure Lowering ammonia should prevent both Might prove of value in patients with cirrhosis
13 Several studies highlight role of NH 3 in raising ICP
14 Ornithine Phenyl Acetate: STOP-ALF Trial Lower ammonia to manage cerebral edema Ammonia is the putative cause for cerebral edema OPA traps ammonia and allows renal excretion Could be used prophylactically or as treatment IV, few side effects, might work in cirrhosis also ALFSG has begun to study in APAP patient group
15 OCR-002 Uses Physiological Pathways to Eliminate Nitrogen ornithine OCR-002 phenylacetate Phenacetyl-CoA : Gln acyltransferase PAGN
16 STOP-ALF Trial: Study Features Phase IIa, ALFSG holds the IND Ornithine phenylacetate will effectively lower ammonia levels and improve encephalopathy and prevent/control cerebral edema in ALF. First cohort Cr < 1.0 and NH3 > 75 Initial Pilot Study: PK and Safety, 24 patients, ascending dose Six high enrolling sites: UCSF, Penn, VCU, Michigan, MUSC, UTSW Drug and all PK monitoring and NH3 labs supplied by Ocera
17 STOP-ALF Trial: Early Results 29 APAP pts screened at the 6 sites/57 pts overall 27 screen failures/2 patients enrolled! Reasons for screen failures: High Cr (Acute Kidney Injury) 13 (45%) Low Ammonia (< 75 µmol/l) 11 (41%) Administrative glitches 2 (7%)
18 Ammonia and creatinine levels for 355 acetaminophen pts.
19 STOP-ALF Trial: Other Scenarios
20 STOP-ALF Trial: Lessons Learned Initial criteria were too stringent, excluded many patients! Acetaminophen toxicity is very commonly associated with kidney injury, ~ 70% of the time. High ammonia levels are associated with kidney injury. Also, broadening criteria to include presumed acetaminophen, since many patients cannot give a history at the time of presentation. Meeting with FDA is resulting in protocol revisions.
21 Summary Hepatic encephalopathy = acute liver failure Seen in both APAP and DILI Cerebral edema mostly in APAP and high NH 3 Agents are not directed at lowering NH 3 New agents will determine whether this strategy is effective.
22 Study Sites (Adult) in the ALFSG UT Southwestern Lee/Larson/Sanders U Washington Liou UCSF Fix Mt. Sinai NYC Liu/Zuniga Univ Nebraska Omaha McCashland/Teten Baylor Dallas Murray/Coultrup Univ Pittsburgh Shakil/Gooch Northwestern University Ganger/Gottstein OHSU, Portland Zaman/Ingram/Wilson UCLA McClune/Peacock/Melgoza Michigan Fontana/Welch Univ Alabama Birmingham McGuire/Hogue Mass General Chung/Rutherford/Lundmark/Gustafson Columbia/Cornell NYC Brown/Odeh-Ramadan VCU Stravitz/White/Topaz Mayo Clinic: Rochester, Jax Hay, Raj,Kramer: Groettum/Kontras UC Davis Rossaro/Dhaliwal Einstein Philadelphia Munoz/Riera/Carmody MUSC Charleston Reuben/Minshall Pennsylvania Reddy/Wirjosemito Yale University Schilsky/Emre/Engle/Snyder CPMC Davern, Fajardo
23
New Developments in the Management of Acute Liver Failure. Oren Fix, MD, MSc, FACP Assistant Professor of Medicine Division of Gastroenterology
New Developments in the Management of Acute Liver Failure Oren Fix, MD, MSc, FACP Assistant Professor of Medicine Division of Gastroenterology Learning Objectives Describe 3 new approaches to the management
More informationAcute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality
Acute Liver Failure in the USA 2011 Evaluation of diagnostic criteria to approach DILI causality William M. Lee, MD Professor of Internal Medicine Meredith Mosle Chair in Liver Diseases UT Southwestern
More informationWilliam M. Lee, MD. Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips William M. Lee, MD Clinical Professor Department of Internal Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationAim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips DILI 2014: Aims/Topics Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury William M. Lee, MD Clinical
More informationAcute Liver Failure UCSF Critical Care Medicine and Trauma Meeting June 6, 2008 Tim Davern, MD UCSF Liver Transplant Program
Acute Liver Failure UCSF Critical Care Medicine and Trauma Meeting June 6, 2008 Tim Davern, MD UCSF Liver Transplant Program timothy.davern@ucsf.edu Acute Liver Failure - Outline - Incidence Definition
More informationCurrent Concepts in Diagnosis and Management of Acute Liver Failure
Current Concepts in Diagnosis and Management of Acute Liver Failure Oren Fix, MD, MSc, FACP, AGAF, FAASLD Medical Director, Liver Transplant Program Swedish Medical Center Seattle, WA Learning Objectives
More informationAcute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
More informationAcute Liver Failure. Critical Care Medicine and Trauma Course May 30, 2000
Acute Liver Failure Critical Care Medicine and Trauma Course May 30, 2000 Tim Davern, MD Director - Acute Liver Failure Program CPMC Liver Transplant Program davernt@sutterhealth.org Acute Liver Failure
More informationTherapies for DILI: NAC, Steroids or NRF-2 activators?
Therapies for DILI: NAC, Steroids or NRF-2 activators? William M. Lee, MD Professor of Internal Medicine Meredith Mosle Chair in Liver Diseases UT Southwestern Medical Center at Dallas Drug-Induced Liver
More informationInnovative Therapeutics for Orphan Liver Disease
Innovative Therapeutics for Orphan Liver Disease Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities
More informationI wish that I had some conflicts to declare
I wish that I had some conflicts to declare reubena@musc.edu Trump s Shavuot I ve got my own commandments, Little Elohim Acute Liver Failure (ALF) [Fulminant Hepatic Failure (FHF)] 1. Hepatic Encephalopathy
More informationHepatic Encephalopathy
Hepatic Encephalopathy John Barber UMassMedical Student, Class of 2019 www.12daysinmarch.com Outline Overview Normal Physiology Pathology Symptoms Diagnosis Treatment Overview Ammonia (NH 3 ) is a byproduct
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationBiology of Hepatic Encephalopathy. School of Medicine Division of Transplantation Immunology & Mucosal Biology MRC Centre for Transplantation
Biology of Hepatic Encephalopathy School of Medicine Division of Transplantation Immunology & Mucosal Biology MRC Centre for Transplantation Pavlov s Physiology Factory 1904: Nobel Prize for developing
More informationThe Natural History of Severe Acute Liver Injury.
The Natural History of Severe Acute Liver Injury. David G. Koch, Medical University of South Carolina J.L. Speiser, Medical University of South Carolina V. Durkalski, Medical University of South Carolina
More informationAcute Hepatitis. Sean G. Kelly, MD
Acute Hepatitis Sean G. Kelly, MD Assistant Clinical Professor Division of Gastroenterology, Hepatology & Nutrition The Ohio State University Wexner Medical Center Acute Hepatitis Overview Viral hepatitis
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationPACT module Acute hepatic failure. Intensive Care Training Program Radboud University Medical Centre Nijmegen
PACT module Acute hepatic failure Intensive Care Training Program Radboud University Medical Centre Nijmegen Acute Liver Failure Acute on Chronic Liver Failure Acute loss of hepatocellular function in
More informationMANAGEMENT OF ACUTE HEPATIC FAILURE
MANAGEMENT OF ACUTE HEPATIC FAILURE -NEW CONCEPT PROF. DR.MD ZAKIR HOSSAIN PROFESSOR & HEAD DEPARTMENT OF MEDICINE RANGPUR MEDICAL COLLEGE & HOSPITAL Rangpur Medical College & Hospital Begum Rokeya Shakhawat
More informationMultiorgan Support Therapies (MOST): Are We Ready? Liver Support Rajiv Jalan UCL Hepatology Royal Free Hospital
CRRT/AKI, workshop, Honore/Jalan/ Noiri/Ricci/Ronco Multiorgan Support Therapies (MOST): Are We Ready? Liver Support Rajiv Jalan UCL Hepatology Royal Free Hospital Disclosures: Inventor: Ornithine phenyl
More informationLiver Disease in the ICU: Acute Liver Failure
Liver Disease in the ICU: Acute Liver Failure Steven C Pugliese, MD Assistant Professor Division of Pulmonary Sciences and Cri@cal Care Medicine University of Colorado Denver 48 y/o male w/out prior liver
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatic Encephalopathy Hepatic Encephalopathy:
More informationLewis W. Teperman, MD The Mary Lea Johnson Richards Organ Transplantation Center at NYU and the ELAD Development Team
Lewis W. Teperman, MD The Mary Lea Johnson Richards Organ Transplantation Center at NYU and the Development Team Bilirubin Improvement Correlates with 90-Day Survival with the Use of the System in a Randomized,
More informationA pathologist, a radiologist and a hepatologist walked into a bar
A pathologist, a radiologist and a hepatologist walked into a bar Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology Saint Louis
More informationUPDATE ON UREA CYCLE DISORDERS TREATMENT
UPDATE ON UREA CYCLE DISORDERS TREATMENT George A. Diaz, MD, PhD Program for Inherited Metabolic Diseases Department of Genetics and Genomic Sciences Icahn School of Medicine at Mount Sinai Disclosure
More informationAcute liver failure (ALF) is that unique concatenation of
2B: Liver Approach to Acute Liver Failure William M. Lee, MD, FACG Acute liver failure (ALF) is that unique concatenation of events when a previously healthy person develops acute hepatic injury of such
More informationAcute Liver Failure. Agenda. Natalie H Bzowej, MD, PhD, FRCPC. Case Introduction Definition Diagnosis Initial Laboratory Evaluation Acetaminophen NAC
Acute Liver Failure Natalie H Bzowej, MD, PhD, FRCPC Agenda Case Introduction Definition Diagnosis Initial Laboratory Evaluation Acetaminophen NAC 1 Case 27 year old female presents to ER with N/V Denies
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More informationOrgan allocation for liver transplantation: Is MELD the answer? North American experience
Organ allocation for liver transplantation: Is MELD the answer? North American experience Douglas M. Heuman, MD Virginia Commonwealth University Richmond, VA, USA March 1998: US Department of Health and
More informationTitle: Treatment of hepatic encephalopathy by on-line hemodiafiltration: A case series study
Author's response to reviews Authors: Shinju Arata (s_arata@yokohama-cu.ac.jp) Katsuaki Tanaka (k_tanaka@urahp.yokohama-cu.ac.jp) Kazuhisa Takayama (k-takayama@star.ocn.ne.jp) Yoshihiro Moriwaki (qqc3@urahp.yokohama-cu.ac.jp)
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationMeasurement of Serum Acetaminophen Protein Adducts in Patients With Acute Liver Failure
GASTROENTEROLOGY 2006;130:687 694 Measurement of Serum Acetaminophen Protein Adducts in Patients With Acute Liver Failure TIMOTHY J. DAVERN II,* LAURA P. JAMES, JACK A. HINSON, JULIE POLSON, ANNE M. LARSON,
More informationACUTE LIVER FAILURE. Aliakbarian M, M.D
ACUTE LIVER FAILURE Aliakbarian M, M.D Acute Liver Failure Definition Rapid deterioration of liver function resulting in altered mentation and coagulopathy in a patient without preexisting cirrhosis and
More informationAlpha-1 Liver Disease
Alpha-1 Liver Disease Jeffrey Teckman, M.D. Professor of Pediatrics and Biochemistry Associate Chair of Pediatrics for Research Director, Pediatric Gastroenterology and Hepatology St. Louis University
More informationPersistent Hyperammonemia Is Associated With Complications and Poor Outcomes in Patients With Acute Liver Failure
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:925 931 Persistent Hyperammonemia Is Associated With Complications and Poor Outcomes in Patients With Acute Liver Failure RAMESH KUMAR,* SHALIMAR,* HANISH
More informationOptimum sodium levels in children with brain injury. Professor Sunit Singhi, Head, Department of Pediatrics, Head, Pediatric
India Optimum sodium levels in children with brain injury Professor Sunit Singhi, Head, Department of Pediatrics, Head, Pediatric Sodium and brain Sodium - the major extracellular cation and most important
More informationVIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms
Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Definitions AST and ALT Markers of hepatocellular injury Ryan M. Ford, MD Assistant Professor of Medicine Director of Viral Hepatitis
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationEmricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension Guadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman,
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationα-glutathione S-Transferase: A New Biomarker for Liver Injury?
α-glutathione S-Transferase: A New Biomarker for Liver Injury? Ian Maina, 1 Jody A. Rule, 1 Frank H. Wians, Jr., 2 Michael Poirier, 3 Lafaine Grant, 1 and William M. Lee, 1 * for the Acute Liver Failure
More informationINSUFICIENCIA HEPATICA AGUDA
INSUFICIENCIA HEPATICA AGUDA NUEVOS MECANISMOS Y NUEVOS TRATAMIENTOS Andres T Blei Northwestern University Feinberg School of Medicine XXVII Jornadas de la Sociedad Canaria de Patologia Digestiva ACUTE
More informationExample Clinician Educational Material for Providers of Immune Effector Cellular Therapy
Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationICP. A Stepwise Approach. Stephan A. Mayer, MD Professor, Neurology & Neurosurgery Director, Neurocritical Care, Mount Sinai Health System
ICP A Stepwise Approach Stephan A. Mayer, MD Professor, Neurology & Neurosurgery Director, Neurocritical Care, Mount Sinai Health System ICP: Basic Concepts Monroe-Kellie doctrine: skull = fixed volume
More informationCase 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks
Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University
More informationNo Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationFOR HKMA CME MEMBER USE ONLY. DO NOT REPRODUCE OR DISTRIBUTE. Influence of High Body Mass Index on Outcome in Acute Liver Failure
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1544 1549 Influence of High Body Mass Index on Outcome in Acute Liver Failure ANNA RUTHERFORD,* TIM DAVERN, J. EILEEN HAY, NATALIE G. MURRAY, TAREK HASSANEIN,
More informationProfessor Peter Hayes University of Edinburgh
Professor Peter Hayes University of Edinburgh Acute liver failure BHIVA meeting, April 2018 No disclosures relevant to this presentation ALF DEFINITIONS Trey and Davidson, 1970 Potentially a reversible
More informationChanging Demographics in Death After Devastating Brain Injury
Changing Demographics in Death After Devastating Brain Injury Andreas H. Kramer MD MSc FRCPC Departments of Critical Care Medicine & Clinical Neurosciences Foothills Medical Center, University of Calgary
More informationAlcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD
Alcoholic Hepatitis: Routine Screening for Early Recognition and Management Juan Guerrero, MD Global Problem 1% of GNP of medium/high income countries Additional societal costs Disproportionately affects
More informationThe Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University
The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and
More informationHepatic Failure/GI/Endocrine Emergencies
Hepatic Failure/GI/Endocrine Emergencies Sukhraj Singh Mudahar, Pharm.D., BCPS John H. Stroger Hospital of Cook County Chicago, Illinois Hepatic Failure/GI/Endocrine Emergencies Sukhraj Singh Mudahar,
More informationTraumatic Brain Injury:
Traumatic Brain Injury: Changes in Management Across the Spectrum of Age and Time Omaha 2018 Trauma Symposium June 15, 2018 Gail T. Tominaga, M.D., F.A.C.S. Scripps Memorial Hospital La Jolla Outline Background
More informationConflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
More informationAcute Liver Failure Fulminant Hepatic Failure
Acute Liver Failure K. Rajender Reddy, M.D. Ruimy Family President s Distinguished Professor in Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical
More informationTreatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management
Treatment of Overt Hepatic Encephalopathy: Focus on Outpatient Management Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationThere is now strong evidence of a central role for
LIVER FAILURE/CIRRHOSIS/PORTAL HYPERTENSION Arterial Ammonia and Clinical Risk Factors for Encephalopathy and Intracranial Hypertension in Acute Liver Failure William Bernal, Catherine Hall, Constantine
More informationMallinckrodt Strategic Acquisition. Ocera Therapeutics, Inc. November 2, 2017
Mallinckrodt Strategic Acquisition Ocera Therapeutics, Inc. November 2, 2017 Forward-looking statements Statements in this document that are not strictly historical, including statements regarding the
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationHepatic Encephalopathy A 2016 perspective Rajiv Jalan UCL Institute for Liver and Digestive Health Royal Free Hospital
Malaga 2016 Hepatic Encephalopathy A 2016 perspective Rajiv Jalan UCL Institute for Liver and Digestive Health Royal Free Hospital Disclosures (Rajiv Jalan): Inventor: Ornithine phenyl acetate for the
More information3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice
3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,
More informationMedicines Protocol HYPERTONIC SALINE 5%
Medicines Protocol HYPERTONIC SALINE 5% HYPERTONIC SALINE 5% v1.0 1/4 Protocol Details Version 1.0 Legal category POM Staff grades Registered Paramedic Registered Nurse Specialist Paramedic (Critical Care)
More information12/4/2017. Disclosure. Educational Objectives. Has been consultant for Bard, Chiesi
Temperature Management in Neuro ICU Kiwon Lee, MD, FACP, FAHA, FCCM Professor of Neurology, RWJ Medical School Chief of Neurology, RWJ University Hospital Director, RWJ Comprehensive Stroke Center Director,
More informationKing s College Hospital NHS Foundation Trust. Acute Liver Disease: what you really need to know.
King s College Hospital NHS Foundation Trust Acute Liver Disease: what you really need to know. William Bernal Professor of Liver Critical Care Liver Intensive Therapy Unit Institute of Liver Studies Kings
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationHepatitis D. Challenges in 2018
Hepatitis D Challenges in 2018 Heiner Wedemeyer Essen University Hospital, Germany Germany Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, AbbVie, Abivax, BMS, Boehringer Ingelheim,
More informationPaired Exchange Results Quarterly Report
Paired Exchange Results Quarterly Report As of September 3, 213 Table of Contents Message From the Founder... 1 Transplants Facilitated by Year... 2 Patient Referrals to NKR Member Centers... 2 New Pair
More informationHome Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia
Home Intravenous Antibiotic Treatment for Intractable Cholangitis in Biliary Atresia Hye Kyung Chang, Jung-Tak Oh, Seung Hoon Choi, Seok Joo Han Division of Pediatric Surgery, Department of Surgery, Yonsei
More informationRenal Care and Liver Disease: Disease Trajectory and Hospice Eligibility
Renal Care and Liver Disease: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources/HEN Course Materials & Disclosure Course materials including
More information4/26/2017. Liver Transplant and Palliative Care: Teaming up to improve care
Liver Transplant and Palliative Care: Teaming up to improve care Jody C. Olson, M.D., FACP Assistant Professor of Medicine and Surgery Hepatology and Critical Care Medicine All patients with end-stage
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationChapter 143 Acetaminophen
Chapter 143 Acetaminophen Episode overview 1) Describe the metabolism of Acetaminophen 2) Describe the 4 stages of Acetaminophen toxicity 3) List 4 mechanism of action of N-acetylcysteine 4) When do you
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationMedical Management of Intracranial Hypertension. Joao A. Gomes, MD FAHA Head, Neurointensive Care Unit Cerebrovascular Center
Medical Management of Intracranial Hypertension Joao A. Gomes, MD FAHA Head, Neurointensive Care Unit Cerebrovascular Center Anatomic and Physiologic Principles Intracranial compartments Brain 80% (1,400
More informationQuarterly Statistical Report
01/04/2008 Page 1 of 26 INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support Quarterly Statistical Report Implant dates: March 1, 2006 November 30, 2007 January 4, 2008 Prepared
More informationThe Burden of Drug Induced Liver Injury
The Burden of Drug Induced Liver Injury Victor J. Navarro, MD Chairman, Division of Hepatology Einstein Healthcare Network Professor of Medicine Jefferson Medical College Philadelphia, PA, USA Victor J.
More informationOver the past 20 years, the Centers for Disease. Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes
VIRAL HEPATITIS Fulminant Hepatitis A Virus Infection in the United States: Incidence, Prognosis, and Outcomes Ryan M. Taylor, 1 Timothy Davern, 2 Santiago Munoz, 3 Stephen-Huy Han, 4 Brendan McGuire,
More informationDIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.
DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. Robert J. de Knegt, Erasmus MC, Rotterdam r.deknegt@erasmusmc.nl Disclosures
More informationLiver Transplantation for Cholangiocarcinoma. John McCall Division of Surgery Dunedin School of Medicine University of Otago
Liver Transplantation for Cholangiocarcinoma John McCall Division of Surgery Dunedin School of Medicine University of Otago Primary Liver Cancer Hepatocellular carcinoma Hepatoblastoma Cholangiocarcinoma
More informationNeurointensive Care of Aneurysmal Subarachnoid Hemorrhage. Alejandro A. Rabinstein Department of Neurology Mayo Clinic, Rochester, USA
Neurointensive Care of Aneurysmal Subarachnoid Hemorrhage Alejandro A. Rabinstein Department of Neurology Mayo Clinic, Rochester, USA The traditional view: asah is a bad disease Pre-hospital mortality
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 7
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 7 Contents 7. Benign liver conditions 79 7.1. Pyogenic liver abscess
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationUpdate on Guidelines for Traumatic Brain Injury
Update on Guidelines for Traumatic Brain Injury Current TBI Guidelines Shirley I. Stiver MD, PhD Department of Neurosurgery Guidelines for the management of traumatic brain injury Journal of Neurotrauma
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationTOO COOL OR NOT TOO COOL- THERAPEUTIC HYPOTHERMIA IN THE ICU SCCM TX 2017 TED WU MD PEDIATRIC CRITICAL CARE UNIVERSITY OF TEXAS HEALTH SAN ANTONIO
TOO COOL OR NOT TOO COOL- THERAPEUTIC HYPOTHERMIA IN THE ICU SCCM TX 2017 TED WU MD PEDIATRIC CRITICAL CARE UNIVERSITY OF TEXAS HEALTH SAN ANTONIO DISCLOSURE I have no relationships with commercial companies
More information